Why Barrière Thinks You’ll Want To Wear You Vitamins
Barrière, a wearable vitamin patch company, is expanding into 1,700 Walmart stores and projects $10 million in 2026 revenue. The company claims its transdermal patches deliver supplements through the skin directly into the bloodstream, though experts note clinical evidence for this delivery method is largely lacking. The brand targets younger consumers with stylish, trendy packaging while navigating a largely unregulated supplement industry.
Summary
Barrière is a wearable supplement patch company operating in the $60 billion dietary supplement market, which features around 100,000 products. The company delivers vitamins and herbal ingredients transdermally — through the skin and into the bloodstream — activated by body heat. After a successful test run in about 50 Walmart locations, Barrière announced an exclusive partnership with Walmart to expand into 1,700 stores, bringing its total retail presence to over 6,000 stores. The company projects its 2026 revenue will more than double its 2025 revenue, reaching $10 million, with a current valuation of $19 million.
Barrière's product lineup includes patches for nausea (formulated with ginger, peppermint, and B6), motion sickness, and notably, a lactose intolerance relief patch — which the company claims is the first of its kind in the world. Products retail between $13 and $18. The brand cites rising health consciousness among younger consumers, fueled by social media platforms like TikTok and Instagram, as a key driver of demand. The broader cultural context includes the Make America Healthy Again movement and RFK Jr.'s declaration that the FDA would end its 'war on vitamins.'
Despite the company's growth, experts raise concerns about the clinical efficacy of transdermal supplement delivery. A medical expert interviewed noted that the assumption that small molecules will penetrate skin and achieve bioavailability lacks strong clinical evidence, contrasting it with well-documented oral supplementation studies. Barrière's own clinical trial involved only 30 subjects and lacked a control group. The CEO acknowledged that rigorous clinical trials have been cost-prohibitive and are not legally required to sell supplements in the US, but stated the company plans to pursue them within 3 to 5 years.
The regulatory environment compounds these concerns. Under the Dietary Supplement Health and Education Act of 1994, supplements are classified as food products rather than pharmaceuticals, leaving product safety largely up to companies. A survey found that 48% of consumers incorrectly believe the FDA regulates supplements the same way as prescription drugs. Barrière attempts to differentiate itself through transparency and quality measures: its products are manufactured in the UK at FDA-equivalent regulated facilities and tested in third-party labs, neither of which is legally required. The company frames its mission as solving not just biological efficacy, but the behavioral challenge of helping consumers maintain healthy daily habits.
Key Insights
- Barrière's CEO acknowledges that rigorous clinical trials are cost-prohibitive and not legally required to sell supplements in the US, and the one trial the company conducted had only 30 subjects and no control group.
- A medical expert argues that clinical evidence for transdermal supplement bioavailability is lacking, and that oral supplementation has documented studies showing it corrects nutrient deficiencies — whereas a patch with vitamin D, for example, does not have comparable evidence.
- Barrière claims to have created the first lactose relief patch in the world, positioning it as a one-patch-a-day solution for all-day dairy freedom.
- A medical expert contends that marketing is usually way ahead of science in the supplement industry, and that consumers are choosing convenience over clinical efficacy with products like wearable patches.
- Nearly half of survey respondents — 48% — incorrectly believe the FDA regulates dietary supplements the same way as prescription drugs, reflecting a widespread misunderstanding of the supplement industry's largely self-regulated nature.
Topics
Transcript
[0:00] Young people are prioritizing their health, and it's showing up on company balance sheets. The dietary supplement market is a highly competitive $60 billion industry, with around 100,000 products available to consumers. And a new way to take these supplements is emerging in the market. Wearable patches. Barriére is one of the companies leading the charge. It told CNBC exclusively that it's partnered with Walmart to roll out its products in 1700 stores after a successful test run in about 50 Walmart locations last year. The company projects [0:31] its 2026 revenue to more than double 2025 revenue and reach $10 million, with a current valuation of $19 million. As of today, we are in over 6000 stores, with…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Why It’s So Hard To Build An AI Kill Switch
The video explores whether an AI kill switch is technically feasible and practically implementable. While experts acknowledge the need for safety mechanisms, they conclude that a single universal kill switch is impossible due to distributed computing infrastructure, and that comprehensive regulation similar to other industries would be more effective than a technological quick fix.
America’s AI Chip Talent Crisis — Why The U.S. Needs 157,000 More Workers
The U.S. faces a critical shortage of 157,000 semiconductor workers by the end of the decade as major chip manufacturers build advanced fabs domestically. Universities like Purdue and Arizona State are launching hands-on semiconductor programs, while companies are recruiting aggressively and investing heavily in workforce development to close the talent gap that currently exists compared to Asia.
Exclusive look inside SK Hynix's $720 billion AI memory expansion
SK Hynix, the world's leading maker of high-bandwidth memory (HBM) chips for AI, is investing $720 billion to triple production capacity by 2034 in response to unprecedented demand from major tech companies. The company is expanding aggressively across South Korea and into the US, but faces the classical risk of the memory industry's boom-and-bust cycles.
Why airfare is unlikely to go down
Airfare prices are unlikely to decrease this summer despite recent drops in fuel costs, as the four largest US airlines control over 82% of US seats and face no customer resistance to higher fares. The collapse of discount competitor Spirit Airlines has removed tens of millions of affordable seats from the market, further reducing pricing pressure.
Why Otis isn't focused on building new elevators
Otis, the world's largest elevator company, invests heavily in testing and maintenance rather than new elevator development. Since spinning off from United Technologies in 2020, Otis has grown sales by 13% and now services 2.5 million elevators annually, though its stock has underperformed the industrial sector recently.